

Investigating the Effects of Icovamenib in Poorly Managed Severe Insulin-Deficient Diabetes (SIDD): Insights from COVALENT-111 Case Studies

Abstract #0063

We Aim to Cure™

Alexander Abitbol, MDCM, FRCPC¹; Douglas Denham, DO²; Apinya B. Vutikullird, DO³; Adolfo Cueli, MD⁴; Alexander Osowa, MD⁵; Sanchita Mourya, MD⁶; Brian Munneke, PhD⁶; Jeffrey Kim, PhD⁶; Thomas Butler, MS, MBA⁶; Juan Pablo Frías, MD⁶

¹Centricity Research/LMC, 1929 Bayview Avenue, Suite 125 & 107 Toronto, Ontario M4G 3E8 Canada; ²Flourish Research, 5430 Fredericksburg Rd. Ste 200 San Antonio, TX 78229 USA; ³Ark Clinical Research, LLC, 2220 Clark Ave. Unit A Long Beach, CA 90815 USA;

⁴Entrust Clinical Research, 10621 North Kendall drive suite 218, Miami FL, 33176 USA; ⁵Omera Health, 757 60th Street, BROOKLYN, NY 11220 USA; ⁶Biomea Fusion, 900 Middlefield Rd, 4th Floor, Redwood City, CA 94063 USA

Background

Type 2 Diabetes (T2D)

- T2D is characterized by hyperglycemia due to a progressive decline in beta-cell mass and function
- At diagnosis, beta-cell function is typically reduced by over 50%, with further decline as the disease progresses¹
- Current treatments do not specifically address this underlying beta-cell dysfunction
- There is an important unmet need to develop T2D treatments that address the core defect of the disease: the loss of insulin-secreting beta cells

Menin

- Menin is a ubiquitous scaffold protein that displays tissue-specific roles through regulating gene expression and cell signaling pathways, dependent on various menin-bound protein complexes
- Menin is a key negative regulator of both beta-cell proliferation and mass

Icovamenib


- Icovamenib is an oral, selective, covalent menin inhibitor that is currently in clinical development for the treatment of T2D (NCT05731544) and type 1 diabetes (T1D) (NCT06152042)
- In Zucker Diabetic Fatty and streptozotocin-induced T2D rat models, a short-course of icovamenib resulted in durable glycemic control^{2,3}
- In human islet microtissues, icovamenib exposure resulted in beta-cell proliferation in the presence of hyperglycemia that was dependent on icovamenib dose and duration of exposure⁴
- In poorly controlled patients with T2D, 4-weeks of icovamenib (100mg or 200mg daily) resulted in durable improvements in glycemic control. At Week 26, 22 weeks after completion of the 4-week course of icovamenib⁵:

- ≥1.0% HbA_{1c} reduction in 20% and 36% of patients treated with 100mg (n=20) and 200mg (n=11) daily, respectively
- Across 100 and 200-mg cohorts (n=31): 26% of patients had ≥1.0% HbA_{1c} reduction (mean HbA_{1c} reduction 1.5%)
- In patients with poorly controlled diabetes, efficacy and safety of up to 12 weeks of icovamenib, with subsequent follow-up until week 52, is being assessed to test the hypothesis that a longer duration of therapy will result in greater improvements in durable glycemic control

COVALENT-111 (Escalation Phase): Study Overview & Design

Study Design: 26-week, randomized, double-blind, placebo-controlled

Subjects: Adults with T2D (duration ≤15 years, HbA_{1c} 7-10.5%, BMI 25-40 kg/m²) and treated with up to 3 antidiabetic agents



T2D Heterogeneity and Subtyping

- T2D is highly heterogeneous in clinical characteristics, progression, drug response, and complication risks
- Ahlqvist et al.⁶ identified five adult-onset diabetes subtypes using: GAD autoantibodies, age at onset, HbA_{1c}, BMI, insulin resistance (HOMA2-IR), and insulin secretion (HOMA2-B):

- Severe Autoimmune Diabetes (SAID)
- Severe Insulin-Deficient Diabetes (SIDD)
- Severe Insulin-Resistant Diabetes (SIRD)
- Mild Obesity-Related Diabetes (MOD)
- Mild Age-Related Diabetes (MARD)

T2D Subtypes


Key subtype differences:

- Complication risks
- Disease progression
- Genetic factors
- Treatment responses
- Insulin Resistance
- Insulin Deficient


Benefits of subtyping:

- Framework for personalized and precision medicine
- Improved resource allocation and research focus

Subtype Clustering: Subtype assignment performed post-hoc using diabetes clusters proposed by Ahlqvist et al.⁶



Reduction of HbA_{1c} in Beta-Cell Deficient vs Insulin Resistant Patients



Placebo-adjusted change in HbA_{1c} by T2D subtype at Week 26*

*includes Cohorts 2,3,4 & 7 (100mg QD/BID and 200mg QD, cohorts representative of exposure expected in expansion phase, Arms A-C)

Conclusions


- Icovamenib is an investigational covalent menin inhibitor in development to address the root cause of diabetes: the progressive decline in beta-cell mass and function
 - COVALENT-111 (Escalation Phase) assesses the efficacy and safety of 4-week once daily administration of icovamenib in T2D to address this important unmet need in this patient population
- T2D subtyping reveals distinct risk profiles and provides a framework for precision medicine
 - Enhancing the power of experimental and clinical studies through more homogeneous patient populations
- Case studies demonstrate the potential of short-term icovamenib treatment to modify disease progression and provide lasting effects in patients with uncontrolled T2D
 - Many patients showed continued improvement in HbA_{1c} levels and time in range on CGM until Week 26 after completing 4 weeks of treatment; the first patient presented here showed continued improvement beyond Week 26 of study follow-up
 - The observed increases in HOMA-B and C-peptide, which correlate with improved glycemic control, align with icovamenib's primary mechanism of action: enhancing beta-cell mass and function
- COVALENT-111 is ongoing, and results of the Expansion Phase, consisting of data from over 200 patients dosed with icovamenib, are currently being analyzed and prepared for dissemination

References

- Wysham C, Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. *Postgrad Med.* 2020 Nov;132(8):676-686.
- Butler T. et al. Oral Long-Acting Menin Inhibitor Normalizes Type 2 Diabetes Mellitus (T2DM) in Two Rat Models. *Diabetes*, 2022 Jun 1; 71 (Supplement_1): 851-P.
- Somanath P. et al. Oral Menin Inhibitor, BMF-219, Displays a Significant and Durable Reduction in HbA_{1c} in a Type 2 Diabetes Mellitus Rat Model. *Diabetes*, 2022 Jun 1; 71 (Supplement_1): 113-LB.
- Frías J. et al. BMF-219: A Novel Therapeutic Agent to Re-Establish Functional Beta Cells and Provide Long-Term Glycemic Control. *Metabolism-Clinical and Experimental*, 2024: 0088.
- Rodriguez J. et al. Durable Glycemic Control With BMF-219 During Off-treatment Period At Week 26: A Phase 1/2 Trial Of BMF-219 In Patients With Type 2 Diabetes. *Diabetes Technol Ther*, 2024; 26:S2: PD064.
- Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol.* 2018;6(5):361-369.

Severe Insulin-Deficient Diabetes Case #1

- 29-year-old man with 4-year history of T2D, SIDD classification
- Metformin 1000 mg BID and empagliflozin 25 mg BID
- At baseline, HbA_{1c} 9.5%; FPG 134 mg/dL; CGM with 34% TIR₇₀₋₁₈₀ mg/dL; BMI 25.6 kg/m²
- Icovamenib 200 mg once daily for 4 weeks
- At Week 26, HbA_{1c} 7.0% (-2.5%), FPG 105 mg/dL (-29 mg/dL), HOMA-B increased by 190%, and C-peptide increased by 71%
- CGM at Week 26 with 90% TIR₇₀₋₁₈₀ mg/dL (+56%)
- No adverse events
- The patient's endocrinologist observed additional HbA_{1c} reduction at Week 36, adjusting metformin to 500 mg BID. By Week 47, HbA_{1c} dropped to 5.8% and metformin discontinued



Severe Insulin-Deficient Diabetes Case #2

- 45-year-old man with 10-year history of T2D, SIDD classification
- Metformin 500 mg BID
- At baseline, HbA_{1c} 8.6%; FPG 235 mg/dL; CGM with 4% TIR₇₀₋₁₈₀ mg/dL; BMI 29.6 kg/m²
- Icovamenib 100 mg once daily with food for 4 weeks
- At Week 26, HbA_{1c} 7.5% (-1.1%), FPG 144 mg/dL (-91 mg/dL), HOMA B increased by 1233%, and C-peptide increased by 59%
- CGM at Week 26 with 79% TIR₇₀₋₁₈₀ mg/dL (+73%)
- No adverse events reported

